Upregulation of CENPF is linked to aggressive features of osteosarcoma Retraction in /10.3892/ol.2023.14134

Zou,Ping-An; Yang,Zheng-Xu; Wang,Xi; Tao,Zhi-Wei

doi:10.3892/ol.2021.12909

Upregulation of CENPF is linked to aggressive features of osteosarcoma

Retraction in: /10.3892/ol.2023.14134

Authors:
- Ping-An Zou
- Zheng-Xu Yang
- Xi Wang
- Zhi-Wei Tao
View Affiliations

Affiliations: Department of Bone and Soft Tissue Oncology, Jiangxi Cancer Hospital, Nanchang, Jiangxi 330029, P.R. China
Published online on: July 9, 2021 https://doi.org/10.3892/ol.2021.12909
Article Number: 648
Copyright: © Zou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Centromere protein F (CENPF) plays a key role in the regulation of the cell cycle. The present study revealed that CENPF was overexpressed in a variety of tumors and associated with the poor prognosis of osteosarcoma. The mRNA expression levels of CENPF were analyzed using the Gene Expression Profiling Interactive Analysis database and the protein levels of CENPF were detected in the specimens from patients with osteosarcoma using immunohistochemistry. Cell proliferation, cell cycle and flow cytometry assays were performed after the transfection of control or CENPF plasmids into osteosarcoma cells. A xenografts assay was used to determine the effects of CENPF on tumor growth in vivo. The results showed that CENPF was upregulated in osteosarcoma tissues and associated with high‑grade tumor stage (P=0.023) and intraglandular dissemination (P=0.046). The transfection‑induced depletion of CENPF in human osteosarcoma MG‑63 and U‑2 OS cell lines inhibited cell proliferation, stimulated apoptosis and induced cell cycle arrest. Induced CENPF depletion in MG‑63 cells inhibited tumor growth of osteosarcoma cells in mice. These findings suggested that elevated CENPF levels contributed to increased cell proliferation by mediating apoptosis and cell cycle in osteosarcoma. Therefore, CENPF might be a potential biomarker for poor prognosis of osteosarcoma.

View Figures

View References

1	Caudill JS and Arndt CA: Diagnosis and management of bone malignancy in adolescence. Adolesc Med State Art Rev. 18:62–78. 2007.PubMed/NCBI
2	Sissons HA: The WHO classification of bone tumors. Recent Results Cancer Res. 54:104–108. 1976.PubMed/NCBI
3	Mason NJ: Comparative immunology and immunotherapy of canine osteosarcoma. Adv Exp Med Biol. 1258:199–221. 2020. View Article : Google Scholar : PubMed/NCBI
4	von Eisenhart-Rothe R, Toepfer A, Salzmann M, Schauwecker J, Gollwitzer H and Rechl H: Primary malignant bone tumors. Orthopade. 40:1121–1142. 2011.(In German). View Article : Google Scholar : PubMed/NCBI
5	Jaffe N, Carrasco H, Raymond K, Ayala A and Eftekhari F: Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery? Cancer. 95:2202–2210. 2002. View Article : Google Scholar : PubMed/NCBI
6	Berto A, Yu J, Morchoisne-Bolhy S, Bertipaglia C, Vallee R, Dumont J, Ochsenbein F, Guerois R and Doye V: Disentangling the molecular determinants for Cenp-F localization to nuclear pores and kinetochores. EMBO Rep. 19:e447422018. View Article : Google Scholar : PubMed/NCBI
7	Shahid M, Lee MY, Piplani H, Andres AM, Zhou B, Yeon A, Kim M, Kim HL and Kim J: Centromere protein F (CENPF), a microtubule binding protein, modulates cancer metabolism by regulating pyruvate kinase M2 phosphorylation signaling. Cell Cycle. 17:2802–2818. 2018. View Article : Google Scholar : PubMed/NCBI
8	Erlanson M, Casiano CA, Tan EM, Lindh J, Roos G and Landberg G: Immunohistochemical analysis of the proliferation associated nuclear antigen CENP-F in non-Hodgkin's lymphoma. Mod Pathol. 12:69–74. 1999.PubMed/NCBI
9	Cheng Y, Wang K, Geng L, Sun J, Xu W, Liu D, Gong S and Zhu Y: Identification of candidate diagnostic and prognostic biomarkers for pancreatic carcinoma. EBioMedicine. 40:382–393. 2019. View Article : Google Scholar : PubMed/NCBI
10	Sun J, Huang J, Lan J, Zhou K, Gao Y, Song Z, Deng Y, Liu L, Dong Y and Liu X: Overexpression of CENPF correlates with poor prognosis and tumor bone metastasis in breast cancer. Cancer Cell Int. 19:2642019. View Article : Google Scholar : PubMed/NCBI
11	Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Sun B, Lin G, Ji D, Li S, Chi G and Jin X: Dysfunction of sister chromatids separation promotes progression of hepatocellular carcinoma according to analysis of gene expression profiling. Front Physiol. 9:10192018. View Article : Google Scholar : PubMed/NCBI
14	Alghamdi M, Alkhamis WH, Bashiri FA, Jamjoom D, Al-Nafisah G, Tahir A and Abdouelhoda M: Expanding the phenotype and the genotype of Stromme syndrome: A novel variant of the CENPF gene and literature review. Eur J Med Genet. 63:1038442020. View Article : Google Scholar : PubMed/NCBI
15	Chen EB, Qin X, Peng K, Li Q, Tang C, Wei YC, Yu S, Gan L and Liu TS: HnRNPR-CCNB1/CENPF axis contributes to gastric cancer proliferation and metastasis. Aging (Albany NY). 11:7473–7491. 2019. View Article : Google Scholar : PubMed/NCBI
16	Li R, Wang X, Zhao X, Zhang X, Chen H, Ma Y and Liu Y: Centromere protein F and forkhead box M1 correlation with prognosis of non-small cell lung cancer. Oncol Lett. 19:1368–1374. 2020.PubMed/NCBI
17	Liu ZK, Zhang RY, Yong YL, Zhang ZY, Li C, Chen ZN and Bian H: Identification of crucial genes based on expression profiles of hepatocellular carcinomas by bioinformatics analysis. PeerJ. 7:e74362019. View Article : Google Scholar : PubMed/NCBI
18	Mahmoud AD, Ballantyne MD, Miscianinov V, Pinel K, Hung J, Scanlon JP, Iyinikkel J, Kaczynski J, Tavares AS, Bradshaw AC, et al: The human-specific and smooth muscle cell-enriched lncRNA SMILR promotes proliferation by regulating mitotic CENPF mRNA and drives cell-cycle progression which can be targeted to limit vascular remodeling. Circ Res. 125:535–551. 2019. View Article : Google Scholar : PubMed/NCBI
19	Lokody I: Signalling: FOXM1 and CENPF: Co-pilots driving prostate cancer. Nat Rev Cancer. 14:450–451. 2014. View Article : Google Scholar : PubMed/NCBI
20	Lin SC, Kao CY, Lee HJ, Creighton CJ, Ittmann MM, Tsai SJ, Tsai SY and Tsai MJ: Dysregulation of miRNAs-COUP-TFII-FOXM1-CENPF axis contributes to the metastasis of prostate cancer. Nat Commun. 7:114182016. View Article : Google Scholar : PubMed/NCBI
21	Aytes A, Mitrofanova A, Lefebvre C, Alvarez MJ, Castillo-Martin M, Zheng T, Eastham JA, Gopalan A, Pienta KJ, Shen MM, et al: Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell. 25:638–651. 2014. View Article : Google Scholar : PubMed/NCBI
22	Li Z, Sang M, Tian Z, Liu Z, Lv J, Zhang F and Shan B: Identification of key biomarkers and potential molecular mechanisms in lung cancer by bioinformatics analysis. Oncol Lett. 18:4429–4440. 2019.PubMed/NCBI
23	Zhang JY, Zhu W, Imai H, Kiyosawa K, Chan EK and Tan EM: De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma. Clin Exp Immunol. 125:3–9. 2001. View Article : Google Scholar : PubMed/NCBI
24	Hong Y, Long J, Li H, Chen S, Liu Q, Zhang B, He X, Wang Y, Li H, Li Y, et al: An analysis of immunoreactive signatures in early stage hepatocellular carcinoma. EBioMedicine. 2:438–446. 2015. View Article : Google Scholar : PubMed/NCBI
25	Li S, Li X, Xu A, Zhang B, He X, Chen H and Huang J: Screening and clinical evaluation of dominant peptides of centromere protein F antigen for early diagnosis of hepatocellular carcinoma. Mol Med Rep. 17:4720–4728. 2018.PubMed/NCBI
26	Wan Z, Zhang X, Luo Y and Zhao B: Identification of hepatocellular carcinoma-related potential genes and pathways through bioinformatic-based analyses. Genet Test Mol Biomarkers. 23:766–777. 2019. View Article : Google Scholar : PubMed/NCBI
27	Yang X, Miao BS, Wei CY, Dong RZ, Gao PT, Zhang XY, Lu JC, Gao C, Wang XY, Sun HC, et al: Lymphoid-specific helicase promotes the growth and invasion of hepatocellular carcinoma by transcriptional regulation of centromere protein F expression. Cancer Sci. 110:2133–2144. 2019. View Article : Google Scholar : PubMed/NCBI
28	Kim HE, Kim DG, Lee KJ, Son JG, Song MY, Park YM, Kim JJ, Cho SW, Chi SG, Cheong HS, et al: Frequent amplification of CENPF, GMNN and CDK13 genes in hepatocellular carcinomas. PLoS One. 7:e432232012. View Article : Google Scholar : PubMed/NCBI
29	Göbel C, Özden C, Schroeder C, Hube-Magg C, Kluth M, Möller-Koop C, Neubauer E, Hinsch A, Jacobsen F, Simon R, et al: Upregulation of centromere protein F is linked to aggressive prostate. cancers. Cancer Manag Res. 10:5491–5504. 2018. View Article : Google Scholar
30	O'Brien SL, Fagan A, Fox EJ, Millikan RC, Culhane AC, Brennan DJ, McCann AH, Hegarty S, Moyna S, Duffy MJ, et al: CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. Int J Cancer. 120:1434–1443. 2007. View Article : Google Scholar
31	Zhuo YJ, Xi M, Wan YP, Hua W, Liu YL, Wan S, Zhou YL, Luo HW, Wu SL, Zhong WD and Wu CL: Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer. Int J Mol Med. 35:966–972. 2015. View Article : Google Scholar : PubMed/NCBI
32	Cao JY, Liu L, Chen SP, Zhang X, Mi YJ, Liu ZG, Li MZ, Zhang H, Qian CN, Shao JY, et al: Prognostic significance and therapeutic implications of centromere protein F expression in human nasopharyngeal carcinoma. Mol Cancer. 9:2372010. View Article : Google Scholar : PubMed/NCBI
33	Dai Y, Liu L, Zeng T, Zhu YH, Li J, Chen L, Li Y, Yuan YF, Ma S and Guan XY: Characterization of the oncogenic function of centromere protein F in hepatocellular carcinoma. Biochem Biophys Res Commun. 436:711–718. 2013. View Article : Google Scholar : PubMed/NCBI
34	Koon N, Schneider-Stock R, Sarlomo-Rikala M, Lasota J, Smolkin M, Petroni G, Zaika A, Boltze C, Meyer F, Andersson L, et al: Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut. 53:235–240. 2004. View Article : Google Scholar : PubMed/NCBI
35	Mi YJ, Gao J, Xie JD, Cao JY, Cui SX, Gao HJ, Yao SP, Liu T, Zhang YY, Guo CH, et al: Prognostic relevance and therapeutic implications of centromere protein F expression in patients with esophageal squamous cell carcinoma. Dise Esophagus. 26:636–643. 2013. View Article : Google Scholar : PubMed/NCBI
36	Laoukili J, Kooistra MR, Brás A, Kauw J, Kerkhoven RM, Morrison A, Clevers H and Medema RH: FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol. 7:126–136. 2005. View Article : Google Scholar : PubMed/NCBI